- Jun 11, 2026
- 2403219710
The demand for glucagon-like peptide 1 (GLP-1) receptor agonists for overweight/obesity has created a clinical conundrum for many primary care providers. Between 2011 and 2023, obesity-specific prescriptions for GLP-1s increased by 700%. Since then, roughly 1 in 5 Americans have reportedly taken these drugs to lose weight...
GET PAID FOR SHOPPING AT ALL YOUR FAVORITE STORES!
Sound too good to be true? Here’s the deal: Stores pay us a commission for sending you their way. We share that with you as Cash Back. Everyone wins!
.png)
